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Background/aim: Vitamin D levels have been investigated in children with familial Mediterranean fever (FMF), but the relationship
between vitamin D status and inflammation/oxidative stress indicators could not be clearly demonstrated. This study aimed to investigate the relationship between subclinical inflammation/oxidative stress and vitamin D status in children with FMF during an attack-free
period.
Materials and methods: In the cross-sectional study, ninety children with FMF in the attack-free period and 30 healthy children were
included. Patients were grouped according to their vitamin D status (< 20, 20–29, and 30–100 ng/mL). The groups were compared in
terms of pentraxin 3 (PTX-3), total oxidant status (TOS), and total antioxidant status (TAS). Multivariable linear regression analysis was
performed to identify factors associated with vitamin D status.
Results: PTX-3 levels were significantly higher in patients with vitamin D insufficiency (20-29 ng/mL) than in the group with vitamin
D sufficient (30–100 ng/mL). Patients with vitamin D deficiency (< 20 ng/mL) had higher TOS. A strong negative correlation was observed between vitamin D levels and TOS (p = 0.003). Subclinical inflammation (PTX-3 ≥ 0.640) and high TOS levels were negatively
associated with vitamin D levels.
Conclusion: Subclinical inflammation and oxidative stress were negatively associated with vitamin D levels in patients with FMF during an attack-free period. Sufficient vitamin D levels are important in fighting subclinical inflammation and oxidative stress in children
with FMF.
Key words: Familial Mediterranean fever, inflammation, vitamin D, oxidative stress

1. Introduction
Familial Mediterranean fever (FMF) is an autosomal
recessive, characterized by recurrent fever and
inflammation of the peritoneum, pleura, or synovium.
Patients are generally asymptomatic between attacks, but
subclinical inflammation continues in the attack-free
period in some patients [1–3].
When the MEFV (Mediterranean FeVer) gene is
mutated, the pyrin protein activates caspase-1 and
stimulates excessive IL-1β secretion. IL-1β is responsible
for inducing the synthesis of acute-phase reactants such
as C-reactive protein (CRP), serum amyloid A (SAA),
and pentraxin-3 (PTX-3) [1,4]. PTX-3 levels were found
to be higher in patients with FMF during the attack and
attack-free periods compared to control despite the use
of colchicine. Some researchers have suggested that
PTX-3 can be an indicator of subclinical inflammation

[4–6]. Subclinical inflammation increases the risk of
developing complications such as anemia, heart disease,
and amyloidosis in patients with FMF. Therefore, the
prevention of subclinical inflammation is extremely
important. Additionally, investigations have shown that
oxidative stress increases in patients with FMF during
attack and the attack-free periods [7,8]. In this study,
total oxidant status (TOS) and total antioxidant status
(TAS) were used to determine oxidative stress. TOS and
TAS were detected with practical measurement methods
developed by Erel [9,10].
Vitamin D has been reported to have
immunomodulatory and anti-inflammatory properties
[11,12]. There is a limited number of studies investigating
vitamin D levels in children with FMF [13–15]. To our
knowledge, although these studies determined that
vitamin D levels were lower in children with FMF than in

* Correspondence: didemketi@gmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.

67

ALESH et al. / Turk J Med Sci
healthy controls, the relationship between vitamin D status
and subclinical inflammation/oxidative stress indicators
could not be clearly demonstrated. The aim of this study
was to examine whether there is a relationship between
vitamin D levels and subclinical inflammation/oxidative
stress indicators in FMF patients in the attack-free period.
2. Materials and methods
2.1. Patients and controls
The cross-sectional study was done in the outpatient
clinic of Pediatric Rheumatology at Erciyes University
Hospital between June 1 and August 31, 2020. The current
study was conducted in accordance with the Helsinki
Declaration. Ethical approval was obtained from Erciyes
University, Faculty of Medicine, Ethics Committee for
Clinical Research (2020/93).
Ninety (2–18 age) children with FMF in an attack-free
period, diagnosed according to Yalcınkaya et al. [16] and
regularly followed and treated in the outpatient clinic of
Pediatric Rheumatology were consecutively included in
the study, considering inclusion and exclusion criteria.
In addition, 30 healthy children matched with the patient
group in terms of age and sex were included as the control
group.
Patients with metabolic bone disease, malnutrition,
chronic renal or hepatic failure, and those with chronic
disease accompanying FMF were not included in the
study. Moreover, none of the patients were in the attack
period and used vitamin D supplements or drugs affecting
vitamin D levels.
Ninety children in an attack-free period were grouped
by considering their 25(OH) vitamin D levels according
to the recommendations published by Holick et al. [17].
These subgroups: group 1 (n = 39): child patients with
25(OH) vitamin D status < 20 ng/mL as deficiency;
group 2 (n = 33): child patients with 25(OH) vitamin
D status 20–29 ng/mL as insufficient; group 3 (n = 18):
child patients with 25(OH) vitamin D status 30–100 ng/
mL as sufficient. Also, patients were classified into three
groups, patients with M694V mutation, without M694V
mutation, and mutation-free. We determined the cut-off
value for PTX-3 by ROC analysis. According to this value,
the patients were divided into two groups as those with
subclinical inflammation (PTX-3 ≥ 0.640) and those
without subclinical inflammation (PTX-3 < 0.640) and
their vitamin D levels were compared. In addition, patients
with FMF were divided into subgroups according to their
clinical features and their vitamin D levels were evaluated.
The attack-free period was defined as experiencing no
attack for at least 2 weeks after the last attack.
2.2. Sample collection
After at least 8 h of fasting, morning blood samples were
taken into tubes containing anticoagulant and without
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anticoagulant. All samples from patients and controls were
collected in the same season. Tubes without anticoagulant
were centrifuged for 10 min at 2000 g. Separated serum
samples were transferred to Eppendorf tubes and stored at
-80 °C for 6 months.
2.3. All clinical and laboratory assessments
Age, sex, age at diagnosis, duration of disease, FMF
symptoms, duration of attacks frequency of attacks,
colchicine dose, and its usage duration, genetic mutation
analyzes were obtained during the follow-up period from
the hospital records. The International Severity Scoring
System for FMF (ISSF) criteria (≤ 2 mild, 3-5 intermediate,
≥ 6 severe disease) were used for disease severity scoring
[18].
Serum CRP levels were analyzed on Cobas
c702 autoanalyzer. The measurement of PTH and
25(OH) D vitamin levels was performed by using the
electrochemiluminescence (ECLIA) method on Cobas
e802 immunoassay analyzer (Roche Diagnostics,
Mannheim, Germany). Erythrocyte sedimentation rate
(ESR) was measured in tubes containing anticoagulant on
Vision analyzer (China).
Total oxidant status (TOS) and total antioxidant status
(TAS) were analyzed using the spectrophotometric kit (Rel
Assay Diagnostics, Gaziantep/Turkey). ELISA was utilized
for PTX-3 measurement (YL Biotech, China).
2.4. Statistical analysis
“IBM SPSS Statistics 23” statistical package program
was used to evaluate the data. The compliance of the
data to normal distribution was evaluated using the
histogram and Q-Q plot and Shapiro–Wilk test. Summary
statistics of numerical variables with and without normal
distribution were given as mean ± standard deviation
and median (25% –75% percentile) values, respectively.
Statistical comparisons were done using the Student
t-test and ANOVA for normally distributed data. MannWhitney U and Kruskal-Wallis tests were used for nonnormally distributed data. Post-hoc analyses were done by
using Bonferroni correction. Chi-square test was used for
comparison of categorical variables. Correlation analysis
was done by Pearson or Spearman tests. ROC analysis
was applied to determine the cut-off value for PTX-3.
Multivariable linear regression analysis was performed to
determine the factors associated with serum vitamin D
levels. Independent variables were included in the model
via blockwise entry. Vitamin D level was defined as the
dependent variable. Sex was included in the model as an
independent variable (Model 1). Seasonal difference in the
frequency of attacks, TOS, and PTX3 were added (Model
2). The model fit was checked with a scatter plot of the
predicted value versus residuals, the correlation matrix,
tolerance, or variance inflation factor (VIF). Adjusted
R-square was evaluated of the model. The power analysis
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for calculation of the sample size was done using G*Power
v.3.1.9.2. The required sample size was 30 participants in
each group (control and patient) for serum PTX3 and TOS
(power = 0.80 at α = 0.05). In all statistical comparisons,
the significance level was accepted as p < 0.05.
3. Results
When the age means and sex distribution of the patient and
control groups (11.95 ± 3.95 and 11.55 ± 4.26, p = 0.636,
boy (50% and 56.6%); girl (50% and 43.3%), p = 0.527,
respectively) were compared, no significant difference was
found.
3.1. Clinical Features
The distribution of 90 children with FMF according to
clinical characteristics was shown in Table 1. Twentyfour (26.7%) patients had the seasonal difference in the
frequency of attacks and had more attacks in winter.
Seventy-one (79%) and nineteen (21%) children were
evaluated as mild and moderate, respectively, according to
the disease severity score.
No statistically significant difference was found
between vitamin D and the frequency of the attacks (p =
0.911) and duration of the attacks (p = 0.172) and disease
severity score (p = 0.621), but vitamin D levels were lower
in patients with the seasonal difference in the frequency of
attacks (p = 0.014) (Table 2). Additionally, vitamin D levels
were higher in boys [25.9 (19.95–31.95)] than in the girls
[17.2 (11.65–23.75)] (p < 0.001).
3.2. Genetic Findings
The distribution of the patients according to the M694V
gene mutations was shown in Table 3. Thirty-one (64.4%)
patients had M694V gene mutations. Although vitamin
D levels did not differ between groups with and without
M694 gene mutation, vitamin D levels were found to be
significantly higher in the group mutation-free than in
the patients with gene mutations (p = 0.020) as shown in
Table 3.
3.3. Biochemical Analysis Findings
As seen in Table 4, PTX-3 and TOS levels were higher in
the patient group compared to the control, while the TAS
level was low. No statistically significant differences were
found between the patient and control groups in terms of
vitamin D and PTH levels.
In Table 5, ESR and TAS values did not differ among
the vitamin D subgroups (vitamin D deficiency, vitamin
D insufficient, and vitamin D sufficient) (p = 0.314 and
p = 0.185, respectively). Group 1 (vitamin D deficiency)
and group 2 (vitamin D insufficient) had lower CRP levels
when compared to group 3 (vitamin D sufficient) (p =
0.041).
The percentages of FMF patients with vitamin D
sufficient, insufficient, and deficiency were determined

Table 1. Distribution of patients with FMF according to clinical
characteristics.
Symptoms

n (%)

Abdominal pain

73 (81)

Fever

72 (80)

Arthralgia/arthritis

51 (56)

Chest pain

19 (2)

Rash

2 (2.2)

Attack duration in the last year
≤ 2 days

52 (57.8)

≥3 days

38 (42.2)

Frequency of the attack
≤ 2 / years

41 (45.6)

3-4 / years

4 (4.4)

≥ 5 / years

9 (10)

No attack in the last year

36 (40)

Seasonal difference in attack frequency
No

66 (73.3)

Yes-winter

24 (26.7)

Disease severity score
≤ 2 (mild)

71 (79)

3-5(moderate)

19 (21)

≥ 6 (severe)

-

Treatment
Colchicine

80 (88.9)

Biologic drugs

10 (11.1)

Duration of treatment (years)
Colchicine

5.19 ± 3.67

Biologic drugs

1.92 ± 1.23

Dose of colchicine (mg/day)
0.5–1 mg

75 (83.3)

1.5–2 mg

15 (16.7)

as 20, 36.7, and 43.3, respectively. Thirty percent of the
control group had vitamin D deficiency.
As shown in Figure 1, PTX-3 values differed
significantly among the subgroups (p = 0.028). In the
group 3, PTX-3 levels [0.49 (0.37–1.09)] were lower than
in the group 2 [0.84 (0.63-1.51)] (p = 0.008). PTX-3 levels
did not show difference between sexes (p = 0.738). TOS
values differed significantly between groups separated
according to vitamin D status (p = 0.011). The TOS values
were higher in the group 1 [15.74 (12.00-22.78)] than
in the group 2 [10.56 (8.08–15.57)]. This difference was
statistically significant (p = 0.004).
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Table 2. Comparison of vitamin D levels of patients according to their clinical characteristics
Variables

n

Vitamin D

p

≤ 2 days

52

21.05 (12.15–26.75)

≥3 days

38

24.15 (17.2–29.70)

Duration of the attacks in the last year

0.172

Frequency of the attacks

0.911

≤ 2 / years

41

23.20 (16.70–28.95)

>2 / years

13

21.00 (17.40–30.60)

Disease severity score

0.621

≤ 2 (mild)

71

22.20 (15.6–27.47)

3-5 (moderate)

19

21.0 (12.0–30.67)

No

66

24.55 (16.90–29.20)

Yes-winter

24

17.30 (12.15–22.05)

Seasonal difference in frequency of the attacks

0.014

Data were presented as median (25% - 75% percentile)
Table 3. The comparison of vitamin D levels according to M694V gene mutation.
Mutation

n

%

Vitamin D

p

Patients with M694V mutation

58

(64.4)

21.30 ± 8.15

Patients without M694V mutation

25

(27.7)

22. 03 ± 8.92b

Patients with mutation-free

7

(7.9)

31.20 ± 11.86a,b

a

0.020

Data were presented as n (%), mean ± standard deviation.
Patients with M694V mutation vs mutation-free; p = 0.016a.
Patients without M694V mutation vs mutation-free; p = 0.046b.
Table 4. Comparison of demographic data and some parameters of the patients with FMF and
controls.
Variables

Patients with FMF
(n = 90)

Controls
(n = 30)

p

25 (OH) D (ng/mL)

22.05 (14.93–28.88)

22.70 (17.90–26.35)

0.509

PTH (pg/mL)

27.85 (21.48–36.30)

27.85 (17.98–36.03)

0.490

CRP (mg/L)

0.63 (0.31–2.25)

0.31 (0.17–0.64)

< 0.001

PTX-3 (ng/mL)

0.8 (0.5–1.33)

0.5 (0.4–0.93)

0.004

TAS (μmol/L)

0.97 (0.9–1.06)

1.03 (0.97–1.16)

0.007

TOS(μmol/L)

12.92 (9.30–17.91)

8.24 (6.04–10.42)

< 0.001

Data were presented as median (25%–75% percentile).

A significant negative correlation was observed
between vitamin D and TOS (p = 0.003 rho = –0.308) in
patients with FMF in Figure 2. However, no statistically
significant relation was detected between vitamin D level
and other clinical, laboratory variables in children with
FMF.

70

ROC analysis was applied to determine the cut-off
value for PTX-3 in Figure 3. In the multivariable linear
regression analyses as shown in Table 6, it was found that
girl sex, subclinical inflammation (PTX-3 ≥ 0.640), high
TOS levels and exposure to more attacks in winter were
negatively associated with vitamin D levels in patients with
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Table 5. Comparison of CRP, ESR and TAS according to vitamin D levels.
Variables

Group 1 (n=39)
Vitamin D insufficient

Group 2 (n=33)
Vitamin D deficiency

Group 3 (n=18)
Vitamin D sufficient

P

CRP (mg/L)

0.53 (0.31–1.38)

0.62 (0.30–1.62)

3.72 (0.5–5.28)

0.041

ESR

6.2 (4.25–11.5)

4.57 (2.8–11.25)

6.0 (3.71–12.0)

0.314

TAS (μmol/L)

0.97 (0.93–1.13)

0.96 (0.86–1.08)

0.96 (0.90–1.0)

0.185

Data were presented as median (25%–75% percentile).

Figure 1. Comparison of PTX-3 and TOS values in patient groups.

Group 1: vitamin D deficiency, group 2: vitamin D insufficient, group 3: vitamin D sufficient

FMF. While
the first
model (sex) helped
to explain
Figure
1. Comparison
of PTX-3
and 17.7%
TOS
of the variance, the final model helped to explain 32.4% of
the variance when PTX3, TOS, and seasonal difference in
frequency of the attacks were added.
4. Discussion
Subclinical inflammation generates a hidden threat to the
development of FMF complications such as amyloidosis in
attack-free intervals [3]. In the present study, the difference
in subclinical inflammation (PTX-3), and oxidative stress
indicators (TOS) between the patient and control groups
indicates the presence of subclinical inflammation in the
attack-free period.
Vitamin D levels have been investigated in children
with FMF, but the relationship between vitamin D status
and inflammation/oxidative stress indicators could not be
clearly demonstrated.
Studies have not clarified whether vitamin D deficiency
is a consequence or cause of inflammatory disease. Some
researchers hypothesized that low vitamin D is the
consequence of a chronic inflammatory process caused by
persistent infection [19].

been suggested
valuesItinhaspatient
groupsthat low vitamin D levels in patients

with FMF may induce subclinical inflammation since
vitamin D has an immunomodulatory effect on Th cells and
affects cytokine production [20].
One of the main results of this study is that subclinical
inflammation is one of the factors associated with vitamin
D levels. Multivariable linear regression analysis revealed
that subclinical inflammation was negatively associated with
vitamin D levels in patients with FMF.
Vitamin D both decreases the production of proinflammatory mediators such as IL-1, IL-6, TNF-α and
increases the production of IL 10, an anti-inflammatory
cytokine. Therefore, it has anti-inflammatory activity on
macrophages, dendritic cells, monocytes, and NKs. It has
been determined that the regulation of 1α-hydroxylase in
immune system cells is significantly different from kidneys
and that 1α-hydroxylase is stimulated by cytokines such as
TNF and IFN [11,21-23]. Therefore, we believe that sufficient
vitamin D levels are important in combating subclinical
inflammation.
In previous studies, vitamin D levels in pediatric FMF
patients [13-15,24,25] were lower than controls; it has been
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Figure 2. Correlation of vitamin D with TOS in patients with FMF.

Figure 2. Correlation of vitamin D with TOS in patients with FMF

Figure 3. ROC for PTX-3.

Figure 3. ROC for PTX-3

reported that it is higher in boys than in girls [26]. Kozan
et al. [27], found to be similar vitamin D levels between
patients with FMF and controls. Vitamin D deficiency and
insufficiency were found in 26% and 62% of the children with
FMF, respectively [20]. In another study, 83.3% of the patients
had vitamin D deficiency during the attack-free period [24].
In the present study, vitamin D levels were deficient in 43.3%
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of FMF patients and 30% of controls. However, the similarity
of vitamin D levels with the control may be due to the fact
that the study was planned in the summer months.
Vitamin D levels were sufficient in 20% of patients with
FMF. Additionally, as similar to the other studies [14,15,26],
we found that vitamin D levels were higher in boys than in
girls.
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Table 6. Multivariable linear regression analysis
Unstandardized
Coefficients

Standardized
Coefficients

Beta

Std. Error

Beta

(constant)

18.430

1.214

sex

7.695

1.716

(constant)

26.963

2.247

sex

6.774

1.576

TOS

–0.334

Seasonal difference in
attack frequency
PTX3

Model

1

2

95% Confidence
Interval for B

Collinearity
Statistics

p

Lower
bound

Upper
bound

Tolerance VIF

<0.001

16.018

20.841

<0.001

4.284

11.106

<0.001

22.495

31.430

0.380

<0.001

3.641

0.112

–0.264

0.004

–4.290

1.767

–0.213

–3.456

1.598

–0.190

0.431

1.000

1.000

9.908

0.974

1.027

–0.558

–0.111

0.968

1.033

0.017

–7.804

–0.776

0.990

1.010

0.033

-6.634

–0.278

0.986

1.014

Dependent variable: Vitamin D
Model 1: Independent variable; se
Model 2: Independent variables; sex, TOS, Seasonal difference in frequency of the attacks (no or yes-winter) and
PTX3 (subclinical inflammation no or yes according to cut-off 0.640 for PTX-3).
Model 1: Adjusted R2 = 17.7%
Model 2: Adjusted R2 = 32.4%
Group 1: vitamin D deficiency, group 2: vitamin D insufficient, group 3: vitamin D sufficient.

Erten et al. [26] demonstrated that inflammatory
indicators (ESR and fibrinogen) were correlated with lower
vitamin D levels in adult patients with FMF, although no
relationship was found between the vitamin D levels and
clinical characteristics of child patients or acute phase
reactants in other studies [13-15,24]. Different results
obtained in the study of Erten et al. [26] may be associated
with the age and the higher CRP levels (14.3 ± 34.3
mg/L) of the patients. Similarly, there was no significant
relationship between vitamin D levels and disease severity
score [14,20]. These results were consistent with the
present study.
Studies showed that vitamin D levels are similar in
FMF patients with different MEFV gene mutations. The
most prevalent mutation was detected in the M694V
gene [15,26]. In the present study, M694V was the most
common gene mutation and vitamin D levels were similar
in FMF patients with and without M694V gene mutation.
Patients with gene mutations had lower vitamin D levels
than those gene mutation-free. Further studies are needed
to clarify the relationship between genotype and vitamin D.
It was known that acute phase reactants were higher
in the attack period than in the attack-free period. In a
study, ESR was similar between the attack-free patient
and the healthy groups [5]. However, another study
found that ESR was significantly higher in the attack-free
group compared to the control group [4]. In addition to
studies reporting that CRP levels do not differ between
patient group with attack-free period and control group

[6,8,28], there are also studies showing the opposite [5].
Nevertheless, ESR and CRP were also within normal levels
in the asymptomatic period. Therefore, we think that a
more sensitive indicator could be useful instead of CRP
and ESR in reflecting subclinical inflammation.
Moreover, CRP is an acute phase reactant synthesized
particularly in the liver by the action of proinflammatory
cytokines. PTX-3 is produced as a result of by stimulation
of toll-like receptors (TLRs) and pro-inflammatory
cytokines (IL-1β and TNF-α) and released from peripheral
mononuclear cells [29,30]. Therefore PTX-3 may be more
specific than CRP in reflecting subclinical inflammation. It
has been proposed that vitamin D has immunomodulatory
functions via modulation of TLRs and leads to decrease
expression of TRL2 in autoimmune and pro-inflammatory
based diseases [31]. Therefore, the relationship between
vitamin D and inflammation can be better reflected with
PTX-3. In the present study, PTX3 levels were low in FMF
patients with sufficient vitamin D status.
Gok et al. [4] determined that the PTX-3 level was
higher in young adults in the attack-free period compared
to the control, and PTX-3 had a sensitivity of 90% at a
threshold value of 0.696 ng/mL. In the present study, we
divided the patients into two groups according to cutoff value (0.640) for PTX-3, we found that vitamin D
levels were significantly lower in the patient group with
subclinical inflammation.
Zhang et all. [32] reported that serum vitamin D
levels should be kept above 30 ng/mL to obtain sufficient
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anti-inflammatory effects. In the present study, PTX-3
levels were higher in groups with vitamin D insufficient
compared to the group with sufficient vitamin D. Its
levels of at least 30 ng/mL could be effective in preventing
subclinical inflammation.
Reactive oxygen species (ROS) produced in activated
inflammatory cells by cytokines cause oxidative stress in
patients with FMF [3,10]. The low serum paraoxonase
(PON1) levels and increased lipid peroxidation during
the attack-free period of FMF lead to the continuity
of oxidative stress [25,33]. Although Savran et al. [34]
detected higher TOS in adult patients with FMF compared
to control, TAS results were found to be similar. In another
study, while TAS during the attack and attack-free periods
was lower, TOS was found to be higher than in the control.
Moreover, higher TOS values were detected during the
attack compared to the attack-free period [35].
In the present study, the group with vitamin D
deficiency (< 20 ng/mL) also constituted the group with
the highest TOS values. Vitamin D levels above 20 ng/mL
caused a significant decrease in TOS. TAS did not show
a significant difference between the groups separated
according to vitamin D status. In patients with FMF, the
negative relationship between vitamin D and TOS was
interpreted as vitamin D levels can be effective in reducing
reactive oxygen radicals.
The absence of a diseased control group is one of
the main limitations of the study. Thus, we could not

determine PTX3 in the diseased control group. Vitamin
D levels were not evaluated during attack and attack-free
periods of the disease. The number of patients was low in
groups formed according to vitamin D levels. Additionally,
serum amyloid A levels of patients could not be measured.
In conclusion, the present study showed that subclinical
inflammation and high TOS levels were negatively
associated with vitamin D levels. Sufficient vitamin D levels
are important in fighting subclinical inflammation and
oxidative stress in patients with FMF. Therefore, routine
vitamin D measurement and vitamin D supplementation
can be beneficial for patients with vitamin D deficiency.
We believe that the findings obtained from this study will
gain more value by conducting randomized controlled
studies.
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